481 related articles for article (PubMed ID: 30039550)
21. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
22. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
23. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.
How J; Hobbs GS
J Natl Compr Canc Netw; 2020 Sep; 18(9):1271-1278. PubMed ID: 32886896
[TBL] [Abstract][Full Text] [Related]
24. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
25. Molecular prognostication in Ph-negative MPNs in 2022.
Vannucchi AM; Guglielmelli P
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):225-234. PubMed ID: 36485130
[TBL] [Abstract][Full Text] [Related]
26. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
27. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Bose P; Verstovsek S
Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
[TBL] [Abstract][Full Text] [Related]
28. How I treat myelofibrosis.
Tefferi A
Blood; 2011 Mar; 117(13):3494-504. PubMed ID: 21200024
[TBL] [Abstract][Full Text] [Related]
29. Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM; Harrison CN
Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and management of prefibrotic myelofibrosis.
Rumi E; Sant'Antonio E; Boveri E; Pietra D; Cavalloni C; Roncoroni E; Astori C; Arcaini L;
Expert Rev Hematol; 2018 Jul; 11(7):537-545. PubMed ID: 29862872
[TBL] [Abstract][Full Text] [Related]
31. [Myelofibrosis: A review].
Genthon A; Killian M; Mertz P; Cathebras P; Gimenez De Mestral S; Guyotat D; Chalayer E
Rev Med Interne; 2021 Feb; 42(2):101-109. PubMed ID: 33243417
[TBL] [Abstract][Full Text] [Related]
32. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
[TBL] [Abstract][Full Text] [Related]
33. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI; Levine RL
Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
35. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
37. Myelofibrosis biology and contemporary management.
Gangat N; Tefferi A
Br J Haematol; 2020 Oct; 191(2):152-170. PubMed ID: 32196650
[TBL] [Abstract][Full Text] [Related]
38. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
39. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
40. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
Mudireddy M; Barraco D; Hanson CA; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2017 May; 92(5):454-459. PubMed ID: 28211153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]